CAR-T细胞治疗实体瘤的脱靶效应及优化方略  

Off-target effect and optimization of CAR-T cell therapy in solid tumors

作　　者：彭灿灿 王惠明(指导)[1] PENG Can-Can;WANG Hui-Ming(Department of Nephrology,People's Hospital of Wuhan University,Wuhan 430060,China)

机构地区：[1]武汉大学人民医院肾内科,武汉430060

出　　处：《中国免疫学杂志》2021年第22期2754-2758,共5页Chinese Journal of Immunology

基　　金：国家自然科学基金项目(81172793,81370800);湖北省科技创新重点项目(2019ACA137)。

摘　　要：近年嵌合抗原受体T细胞免疫疗法(CAR-T)发展迅速,在血液系统肿瘤治疗中取得显著疗效。但目前CAR-T疗法在实体肿瘤治疗中仍存在诸多限制,实体肿瘤本身的高度异质性及肿瘤特异性抗原缺乏,是CAR-T研究转向实体瘤治疗的主要障碍,尤其是脱靶效应导致的临床毒性仍是医务研究者目前急需解决的问题。Chimeric antigen receptor T-cell immunotherapy(CAR-T)has evolved rapidly in recent years which has achieved remarkable results in treatment of blood system tumors.However,there were still many limitations in application of CAR-T therapy in solid tumors.High heterogeneity of solid tumors and lack of tumor-specific antigens bring obstacles to transformation of CAR-T research into treatment of solid tumors,especially clinical toxicity caused by off-target effect,which was still an urgent problem for medical researchers.

关 键 词：嵌合抗原受体T细胞免疫疗法 实体肿瘤 肿瘤抗原 脱靶效应 

分 类 号：R392[医药卫生—免疫学]